Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fresenius Kabi AG

Division of Fresenius SE & Co. KGaA
www.fresenius-kabi.com

Latest From Fresenius Kabi AG

US Generics Market Continues To Seek Stability

As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.

BioPharmaceutical Market Intelligence

Pfizer’s FDA-Approved Adalimumab Faces Four-Year Wait

Pfizer has secured FDA approval for its adalimumab biosimilar under the name Abrilada, representing the agency’s 25th biosimilar approval overall. However, patent settlements around the Humira brand mean that Pfizer is not due to enter the market for four years.

Biosimilars United States

US Generics Market Continues To Seek Stability

As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.

Market Intelligence Generic Drugs

Kabi Stretches Adalimumab Presence To Nine Countries

Having started to roll out its Idacio adalimumab biosimilar in Europe earlier this year, Fresenius Kabi is now marketing the Humira rival in nine countries.

Biosimilars Europe
See All

Company Information

UsernamePublicRestriction

Register